Key Points
H2-O deficiency does not predispose to organ-specific or systemic autoimmunity.
H2-O controls the establishment of a chronic γ-herpesvirus infection.
Abstract
H2-O (human HLA-DO) is a relatively conserved nonclassical MHC class II (MHCII)–like molecule. H2-O interaction with human HLA-DM edits the repertoire of peptides presented to TCRs by MHCII. It was long hypothesized that human HLA-DM inhibition by H2-O provides protection from autoimmunity by preventing binding of the high-affinity self-peptides to MHCII. The available evidence supporting this hypothesis, however, was inconclusive. A possibility still remained that the effect of H2-O deficiency on autoimmunity could be better revealed by using H2-O–deficient mice that were already genetically predisposed to autoimmunity. In this study, we generated and used autoimmunity-prone mouse models for systemic lupus erythematosus and organ-specific autoimmunity (type 1 diabetes and multiple sclerosis) to definitively test whether H2-O prevents autoimmune pathology. Whereas our data failed to support any significance of H2-O in protection from autoimmunity, we found that it was critical for controlling a γ-herpesvirus, MHV68. Thus, we propose that H2-O editing of the MHCII peptide repertoire may have evolved as a safeguard against specific highly prevalent viral pathogens.
Footnotes
This work was supported by National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases Grant AI117535 to T.G. and L.K.D., by NIH, National Institute of Allergy and Infectious Diseases Grant AI127411 to A.V.C., and by the National Center for Advancing Translational Sciences of the NIH through Grant UL1 TR000430 to the University of Chicago (P30 CA014599). Other support was provided by The Robert Wood Johnson Foundation (Grant 67038) to the Child Health Institute of New Jersey, and The Barile Children’s Medical Research Trust (to L.K.D.).
The online version of this article contains supplemental material.
Abbreviations used in this article
- ANA
- anti-nuclear Ab
- B6.NZM
- NZM B6J
- EAE
- experimental autoimmune encephalomyelitis
- GC
- germinal center
- GN
- glomerulonephritis
- H2-M
- HLA-DM
- H2-O
- HLA-DO
- KO
- knockout
- KSHV
- Kaposi sarcoma–associated herpesvirus
- MEF
- mouse embryonic fibroblast
- MHCII
- MHC class II
- MOG
- myelin oligodendrocyte glycoprotein
- NZM
- New Zealand mixed
- Oa
- H2-Oa
- Ob
- H2-Ob
- SLE
- systemic lupus erythematosus
- T1D
- type 1 diabetes
- Tfh
- T follicular helper cell
- WT
- wild-type
- Received July 7, 2021.
- Accepted October 14, 2021.
- Copyright © 2021 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.